NEUROCRINE BIOSCIENCES, INC.
NBIX · NASDAQ
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
ESG Scores
Overall ESG4.6
Environmental3.2
Social4.2
Governance4.7
Gender Diversity
Female Directors0.3333%
Female Executives0.10619469026548672%
Women in Workforce0.53%
CEO GenderMale
Market Data
Price$133.25+4.84 (+3.77%)
Market Cap$13.37B
P/E Ratio27.94
EPS$—
52W High$160.18
52W Low$97.30
Beta0.35